Advertisement

Ondansetron Injection

[17 November 2014]

Products Affected - Description

Ondansetron injection, 2mg/mL, AuroMedics
2 mL vials, package of 25 (NDC 55150-0125-02)


Ondansetron injection, 2 mg/mL, Ben Venue Laboratories (formerly Bedford product)
20 mL vial, NDC 55390-0121-01

Ondansetron injection, 2 mg/mL, Fresenius Kabi
2 mL vials, package of 25 (NDC 63323-0373-02)

Zofran injection, 2 mg/mL, GlaxoSmithKline
20 mL vial (NDC 00173-0442-00)
 
Ondansetron injection, 2 mg/mL, Mylan Institutional
2 mL vials, package of 25 (NDC 00069-1340-16)
20 mL vials (NDC 00069-1340-02)
 
Ondansetron injection, 2 mg/mL, Sagent
20 mL vials (NDC 25021-0782-20)
 
Ondansetron injection, 2 mg/mL, Teva
20 mL vials (NDC 00703-7226-01)
20 mL vials, packages of 10 (NDC 00703-7226-03)
 
Ondansetron injection, 2 mg/mL, The Medicines Company
2 mL vials (NDC 65293-0373-25)
20 mL vial (NDC 65293-0374-01)
 
Ondansetron injection, 2 mg\mL, Wockhardt
2 mL vials, packages of 5 (NDC 64679-0726-01)
20 mL vials (NDC 64679-0727-01)

Reason for the Shortage

  • AuroMedics did not provide a reason for the shortage.
  • Caraco temporarily discontinued ondansetron injection.
  • Ben Venue stopped production in its plant in Bedford, Ohio and closed in July, 2014. 
  • Hospira had ondansetron on shortage due to manufacturing delays.
  • Mylan Institutional temporarily discontinued ondansetron 2 mg/mL injectable products in February 2014.
  • Teva temporarily discontinued ondansetron 20 mL injection.
  • West-Ward had ondansetron on back order due to increased demand.
  • Wockhardt has ondansetron injection on shortage due to an FDA import alert.
  • All presentations of ondansetron 32 mg/50 mL premixed bags have been discontinued..

Available Products

Ondansetron injection, 2mg/mL, AuroMedics
20 mL vials (NDC 55150-0126-20)

Ondansetron injection, 2 mg/mL, BD
2 mL prefilled syringe, package of 24 (NDC 76045-0103-20)
 
Ondansetron injection, 2 mg/mL, Fresenius Kabi
20 mL multiple dose vials (NDC 63323-0374-20)
 
Ondansetron injection, 2 mg/mL, Heritage
2 mL vials, package of 10 (NDC 23155-0196-42)
20 mL vials (NDC 23155-0168-31)

Ondansetron injection, 2 mg/mL, Hospira
2 mL vials, packages of 25 (NDC 00409-4755-03)
20 mL vials (NDC 00409-4759-01)
2 mL iSecure syringe (NDC 00406-1120-12)

Ondansetron injection, 2 mg/mL, Sagent
2 mL vials, package of 25 (NDC 25021-0777-02)
 
Ondansetron injection, 2 mg/mL, Teva
2 mL vials, packages of 25 (NDC 00703-7221-04)
 
Ondansetron injection, 2 mg/mL, West-Ward
2 mL vials, packages of 25 (NDC 00641-6078-25)
20 mL vials (NDC 00143-9890-01)
20 mL vials (NDC 00641-6079-01)

Estimated Resupply Dates

  • Auromedics has ondansetron 2 mg/mL 2 mL vials on intermittent back order with regular releases.
  • Fresenius Kabi has ondansetron 2 mg/mL 2 mL vials on back order and the company estimates a release date in mid-January 2015.
  • GlaxoSmithKline has Zofran 2 mg/mL 20 mL vials available with short expiration dating (May 2015).
  • Mylan Institutional has ondansetron 2 mg/mL 2 mL and 20 mL vials on back order and the company cannot estimate a release date.
  • Sagent has ondansetron 2 mg/mL 20 mL vials on back order and the company estimates a release date in December 2014.
  • Teva has ondansetron 2 mg/mL 20 mL presentations on back order and the company estimates a release date in 4th quarter 2014.
  • The Medicines Company has ondansetron 2 mg/mL 2 mL vials on back order and the company cannot estimate a release date. Ondansetron 2 mg/mL 20 mL vials are available with short expiration dating (March 2015) and will be considered out of stock as of January 1, 2015. The company cannot estimate a release date for additional product.
  • West-Ward has all presentations available. Ondansetron 2 mg/mL 20 mL vials are available with good dating as well as short expiration dating (October 2015).
  • Wockhardt has ondansetron 2 mL and 20 mL vials on back order and the company cannot estimate a release date.

Related Shortages

Updated

November 17, 2014; November 7, 2014; October 29, 2014; September 24, 2014; September 3, 2014; August 21, 2014; August 1, 2014; July 7, 2014; June 13, 2014; April 28, 2014; March 31, 2014; March 3, 2014; February 5, 2014; January 24, 2014; December 12, 2013; December 6, 2013; November 20, 2013; October 23, 2013; September 23, 2013; August 14, 2013; July 2, 2013; June 19, 2013; May 30, 2013; May 24, 2013; April 5, 2013; March 8, 2013; February 6, 2013; January 11, 2013; December 13, 2012; November 28, 2012; October 26, 2012; September 19, 2012; August 3, 2012; July 25, 2012; June 28, 2012; May 25, 2012; April 24, 2012; March 28, 2012; February 29, 2012; February 3, 2012; January 20, 2012; December 16, 2011; December 1, 2011; November 23, 2011; October 27, 2011; September 30, 2011; September 19, 2011; January 21, 2011; University of Utah, Drug Information Service. Copyright 2014, University of Utah, Drug Information Service

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement